- Home
- CHNR vs CDT Comparison
CHNR vs CDT Comparison
Compare CHNR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- CDT
- Stock Information
- Founded
- CHNR N/A
- CDT 2019
- Country
- CHNR China
- CDT United States
- Employees
- CHNR N/A
- CDT N/A
- Industry
- CHNR Precious Metals
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- CDT Health Care
- Exchange
- CHNR Nasdaq
- CDT Nasdaq
- Market Cap
- CHNR 4.6M
- CDT 4.6M
- IPO Year
- CHNR 1995
- CDT N/A
- Fundamental
- Price
- CHNR $3.90
- CDT $1.18
- Analyst Decision
- CHNR
- CDT
- Analyst Count
- CHNR 0
- CDT 0
- Target Price
- CHNR N/A
- CDT N/A
- AVG Volume (30 Days)
- CHNR 18.0K
- CDT 160.1K
- Earning Date
- CHNR 05-15-2025
- CDT 08-14-2025
- Dividend Yield
- CHNR N/A
- CDT N/A
- EPS Growth
- CHNR N/A
- CDT N/A
- EPS
- CHNR N/A
- CDT N/A
- Revenue
- CHNR N/A
- CDT N/A
- Revenue This Year
- CHNR N/A
- CDT N/A
- Revenue Next Year
- CHNR N/A
- CDT N/A
- P/E Ratio
- CHNR N/A
- CDT N/A
- Revenue Growth
- CHNR N/A
- CDT N/A
- 52 Week Low
- CHNR $3.16
- CDT $1.16
- 52 Week High
- CHNR $9.04
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- CHNR 54.53
- CDT 24.09
- Support Level
- CHNR $3.57
- CDT $1.47
- Resistance Level
- CHNR $4.24
- CDT $1.36
- Average True Range (ATR)
- CHNR 0.20
- CDT 0.11
- MACD
- CHNR 0.05
- CDT -0.01
- Stochastic Oscillator
- CHNR 59.04
- CDT 3.51
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.